Evidence map›Paper›PMID 42614320›Full record

ReviewFrontiers in immunology2026

Mouse models of B cell lymphomas on the basis of genetic features.

Min Yuan, James Q Wang

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Min YuanDepartment of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China.
James Q WangDepartment of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diffuse large B cell lymphoma (DLBCL) is a highly aggressive form of lymphoma that is genetically and phenotypically diverse. Most DLBCLs arise from the germinal center and transcriptionally represent either germinal center or post-germinal center activated B cells by gene expression profiling. Recently, a revised classification of DLBCLs has identified at least six molecularly defined groups based on their genomic landscape. In this review, we discuss the use of transgenic animal models to study DLBCLs based on the more recent genetic-molecular classification framework. We highlight the importance and insights gained from hallmark animal models of DLBCL, containing over 60 different alleles, and their use in therapeutic discovery.

Indexed as

Disease Models, AnimalLymphoma, B-CellLymphoma, Large B-Cell, DiffuseAnimalsHumansMiceMice, Transgenicdiffuse large B cell lymphomagenetically engineered mouse models (GEMMs)lymphomamouse models and preclinical studiespreclinical (in vivo) studies

Identifiers

PMID42614320
PMCPMC13481496

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.